Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Abingdon Health's Total Stockholders Equity for the quarter that ended in Dec. 2023 was £1.81 Mil. Abingdon Health's Total Assets for the quarter that ended in Dec. 2023 was £4.82 Mil.
Therefore, Abingdon Health's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.38.
The historical rank and industry rank for Abingdon Health's Equity-to-Asset or its related term are showing as below:
LSE:ABDX'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25 Med: 0.57 Max: 0.83
Current: 0.38
During the past 6 years, the highest Equity to Asset Ratio of Abingdon Health was 0.83. The lowest was 0.25. And the median was 0.57.
LSE:ABDX's Equity-to-Asset is ranked worse than 74.89% of 235
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.58
vs LSE:ABDX: 0.38
Abingdon Health Equity-to-Asset Historical Data
The historical data trend for Abingdon Health's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Abingdon Health's Equity-to-Asset
For the Diagnostics & Research subindustry, Abingdon Health's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abingdon Health's Equity-to-Asset Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Abingdon Health's Equity-to-Asset falls into.
Abingdon Health Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Abingdon Health's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abingdon Health (LSE:ABDX) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Abingdon Health Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Abingdon Health's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Abingdon Health PLC is a technology-enabled lateral flow diagnostics company. It provides rapid testing solutions to clients in healthcare and other industries. The firm's product ABC-19 is an antibody test for Covid-19 , and also produces tests covering areas such as self-test HIV, equine infection, human fertility, etc. Business operating segments includes; Contract Development comprises development work for third parties. Contract Manufacturing comprises contract development and manufacturing activities. Product Sales comprises the sale of ABC-19, Pocket Diagnostic products, PCRD tests and antibodies for research use. Key revenue comes from Contract Development segment. Geographically it operates and earns revenue from the UK, USA and Canada, Europe and the rest of the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:ABDX has been successfully added to your 